CN107334818A - A kind of pharmaceutical composition and preparation method and purposes for being used to improve immune function of human body - Google Patents
A kind of pharmaceutical composition and preparation method and purposes for being used to improve immune function of human body Download PDFInfo
- Publication number
- CN107334818A CN107334818A CN201710724860.3A CN201710724860A CN107334818A CN 107334818 A CN107334818 A CN 107334818A CN 201710724860 A CN201710724860 A CN 201710724860A CN 107334818 A CN107334818 A CN 107334818A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- pharmaceutical composition
- human body
- immune function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 31
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 27
- 230000036737 immune function Effects 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 54
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 54
- 239000002994 raw material Substances 0.000 claims abstract description 37
- 239000000284 extract Substances 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 11
- 241001631271 Prunus fasciculata Species 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 4
- 239000003182 parenteral nutrition solution Substances 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 17
- 210000000952 spleen Anatomy 0.000 abstract description 10
- 210000002966 serum Anatomy 0.000 abstract description 7
- 210000001541 thymus gland Anatomy 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 150000002632 lipids Chemical class 0.000 abstract description 5
- 230000000242 pagocytic effect Effects 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 210000001539 phagocyte Anatomy 0.000 abstract description 4
- 239000002245 particle Substances 0.000 description 43
- 238000007796 conventional method Methods 0.000 description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 229920002472 Starch Polymers 0.000 description 13
- 239000008107 starch Substances 0.000 description 13
- 235000019698 starch Nutrition 0.000 description 13
- 239000008108 microcrystalline cellulose Substances 0.000 description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000000469 ethanolic extract Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 229920001353 Dextrin Polymers 0.000 description 8
- 239000004375 Dextrin Substances 0.000 description 8
- 235000019425 dextrin Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 240000002045 Guettarda speciosa Species 0.000 description 6
- 239000002021 butanolic extract Substances 0.000 description 6
- 239000002024 ethyl acetate extract Substances 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 244000000231 Sesamum indicum Species 0.000 description 3
- 235000003434 Sesamum indicum Nutrition 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- -1 pulvis Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000173782 Ficus hirta Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition and preparation method thereof for being used to improve immune function of human body, described pharmaceutical composition by following components and weight than raw material form：The parts by weight of radix fici simplicissimae 8~80, the parts by weight of Radix Angelicae Sinensis 5~60, the parts by weight of ganoderma lucidum 1~30.It is shown experimentally that, the pharmaceutical composition has the function that to improve immune function of human body, influence to indexs such as the phagocyte imdex of immunosuppressed mice, phagocytic index, Thymus and Spleen indexes is better than compatibility group two-by-two, the results showed that has the function that Synergistic between each component.In addition, TC, TG that pharmaceutical composition of the present invention then can be reduced significantly in mice serum are horizontal, there is reducing blood lipid.
Description
Technical field
The invention belongs to drug field, is related to a kind of pharmaceutical composition for being used to improve immune function of human body, particularly relates to
It is and a kind of using traditional Chinese medicine decoction piece extract as the pharmaceutical composition and preparation method for being used to improve body immunity made of raw material.
Background technology
Immunity is the defense mechanism of human body itself, is that human bioequivalence and any foreign matter of the external intrusion of elimination are (viral, thin
Bacterium etc.), processing aging, damage, death, the own cells of denaturation and identification and processing vivo mutations cell and virus are infected thin
The ability of born of the same parents.When immune function of human body is low, just extremely easily cause the infection such as virus, bacterium, fungi, human body is easy for out
A series of diseases such as existing fatigue, flu.Radix fici simplicissimae is commonly used for the replacement of the Radix Astragali for the dry root of Moraceae ficus species ficus simplicissima
Product, therefore also known as southern stilbene, it is a kind of plant of medicine-food two-purpose, has and replenish qi to invigorate the spleen, eliminating the phlegm dampness elimination, the effect of relaxing tendons and activating collaterals, is used for
Deficiency syndrome of the lung asthma due to excessive phlegm, deficiency of spleen-QI and stomach-QI, limb is tired powerless, deficiency of food abdominal distension, oedema, under band, arthralgia pain due to rheumatism, and pain in waist and lower extremities.Planted when being classified as Umbelliferae
The root of thing Radix Angelicae Sinensis, has a benefiting blood and regulating blood circulation, menstruction regulating and pain relieving, the effect of moisturize laxation.Ganoderma lucidum is bracket fungus fungi red sesame or purple sesame
Fructification is dried, there is the effect of invigorating qi for tranquilization, relieving cough and asthma.Now exempt from there are some researches show ganoderma lucidum tool is improved in varying degrees human body
The effect of epidemic disease power, but have no the report on radix fici simplicissimae, Radix Angelicae Sinensis and ganoderma lucidum compatibility.
The content of the invention
It is an object of the invention to solve the deficiencies in the prior art, there is provided and one kind composition is simple, and by natural medicinal raw material
Combination of active principles form have improve immune function of human body pharmaceutical composition.The pharmaceutical composition has good effect,
Have no toxic side effect, be not likely to produce tolerance, it is convenient to take, it is generally applicable to the patient of immunologic hypofunction.
It is another object of the present invention to provide a kind of preparation method of pharmaceutical composition and purposes.The mesh of the present invention
Be achieved through the following technical solutions：A kind of pharmaceutical composition for being used to improve immune function of human body, it is characterised in that：
It by following components and weight than raw material form：
A kind of pharmaceutical composition for being used to improve immune function of human body, it is characterised in that：It is by following components and weight
The raw material composition of ratio：The parts by weight of radix fici simplicissimae 8~80, the parts by weight of Radix Angelicae Sinensis 5~60, the parts by weight of ganoderma lucidum 1~30；Preferably, the five fingers
The parts by weight of wild peach 10~60, the parts by weight of Radix Angelicae Sinensis 8~50, the parts by weight of ganoderma lucidum 3~25；Preferably, the parts by weight of radix fici simplicissimae 15~40,
The parts by weight of Radix Angelicae Sinensis 10~40, the parts by weight of ganoderma lucidum 5~20；Preferably, the parts by weight of radix fici simplicissimae 20~35, the weight of Radix Angelicae Sinensis 15~30
Part, the parts by weight of ganoderma lucidum 8~15；Preferably, the parts by weight of radix fici simplicissimae 30, the parts by weight of Radix Angelicae Sinensis 20, the parts by weight of ganoderma lucidum 10.
A kind of pharmaceutical composition for being used to improve immune function of human body, it is characterised in that：It is by following components and weight
The raw material composition of ratio：The parts by weight of radix fici simplicissimatis extractive 8~80, the parts by weight of angelica extract 5~60, Ganodenna Lucidum P.E 1~30
Parts by weight.Preferably, the parts by weight of radix fici simplicissimatis extractive 30, the parts by weight of angelica extract 20, the parts by weight of Ganodenna Lucidum P.E 10.
A kind of preparation method for being used to improve the pharmaceutical composition of immune function of human body, it is characterised in that：It includes following
Step：
S1：Weigh raw material：Weighed by said components and weight ratio and refer to wild peach, Radix Angelicae Sinensis and ganoderma lucidum；
S2：After raw material is well mixed, adds pharmaceutically acceptable auxiliary material and be prepared into pharmaceutically conventional pharmaceutical preparation.
The pharmaceutical composition of the present invention can be prepared into institute in any pharmacy according to the conventional method of pharmaceutical field
The formulation stated；The pharmaceutical composition of the present invention can be applied to patient by way of oral, suction or parenteral administration.Orally give
Piece agent, capsule, pill, pulvis, granule, syrup or oral liquid etc. can be prepared during medicine；It can be made in parenteral administration
It is standby into freeze-dried powder and parenteral solution etc..
Pharmaceutically acceptable auxiliary material of the present invention includes starch, magnesium stearate, dextrin and microcrystalline cellulose.
Present invention also offers the pharmaceutical composition to prepare the purposes in being used to improve immune function of human body medicine.
To enable above-mentioned formulation to realize, pharmaceutically acceptable auxiliary material need to be added when preparing these formulations, such as：Filling
Agent, disintegrant, lubricant, suspending agent, adhesive, sweetener, flavouring, preservative etc., filler includes：Starch, pregelatinated
Starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose etc., disintegrant includes：Starch, pregelatinized starch, microcrystalline cellulose
Element, sodium carboxymethyl starch, PVPP, low-substituted hydroxypropyl cellulose, Ac-Di-Sol etc., lubrication
Agent includes：Magnesium stearate, lauryl sodium sulfate, talcum powder, silica etc., suspending agent includes：It is polyvinylpyrrolidone, micro-
Crystalline cellulose, sucrose, agar, hydroxypropyl methyl cellulose etc., adhesive includes, starch slurry, polyvinylpyrrolidone, hydroxypropyl
Methylcellulose etc., sweetener includes：Saccharin sodium, aspartame, sucrose, honey element, enoxolone etc., flavouring includes：Sweet tea
Taste agent and various essence, preservative include：Parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, vinegar
Sour chloroethene is fixed, eucalyptus oil etc..
The beneficial effects of the invention are as follows：Pharmaceutical composition has the function that to improve immune function of human body, small to immunosupress
The influence of the indexs such as the phagocyte imdex of mouse, phagocytic index, Thymus and Spleen index is better than compatibility group two-by-two, as a result
Show that there is Synergistic between each component.In addition, pharmaceutical composition of the present invention then can significantly reduce mice serum
In TC, TG it is horizontal, there is reducing blood lipid.
Embodiment
Technical scheme is described in further detail with reference to embodiment, but protection scope of the present invention is not limited to
In as described below.
Embodiment 1：
Raw material radix fici simplicissimae 8g, Radix Angelicae Sinensis 5g, ganoderma lucidum 1g are weighed, pharmaceutic adjuvant is added according to a conventional method and particle is uniformly made,
Tabletting, obtain tablet.
Embodiment 2：
Raw material radix fici simplicissimae 80g, Radix Angelicae Sinensis 60g, ganoderma lucidum 30g are weighed, adds pharmaceutic adjuvant uniformly obtained according to a conventional method
Grain, tabletting, obtains tablet.
Embodiment 3：
Raw material radix fici simplicissimae 10g, Radix Angelicae Sinensis 8g, ganoderma lucidum 3g are weighed, pharmaceutic adjuvant is added according to a conventional method and particle is uniformly made,
Load capsule, obtain capsule.
Embodiment 4：
Raw material radix fici simplicissimae 60g, Radix Angelicae Sinensis 50g, ganoderma lucidum 25g are weighed, adds pharmaceutic adjuvant uniformly obtained according to a conventional method
Grain, load capsule, obtain capsule.
Embodiment 5：
Raw material radix fici simplicissimae 15g, Radix Angelicae Sinensis 10g, ganoderma lucidum 5g are weighed, adds pharmaceutic adjuvant uniformly obtained according to a conventional method
Grain, tabletting, obtains tablet.
Embodiment 6：
Raw material radix fici simplicissimae 40g, Radix Angelicae Sinensis 40g, ganoderma lucidum 20g are weighed, particle is uniformly made according to a conventional method, tabletting, obtains
Tablet.
Embodiment 7：
Raw material radix fici simplicissimae 20g, Radix Angelicae Sinensis 15g, ganoderma lucidum 8g are weighed, particle is uniformly made according to a conventional method, tabletting, obtains piece
Agent.
Embodiment 8：
Raw material radix fici simplicissimae 35g, Radix Angelicae Sinensis 30g, ganoderma lucidum 15g are weighed, particle is uniformly made according to a conventional method, tabletting, obtains
Tablet.
Embodiment 9：
Raw material radix fici simplicissimae 30g, Radix Angelicae Sinensis 20g, ganoderma lucidum 10g are weighed, particle is uniformly made according to a conventional method, tabletting, obtains
Tablet.
Embodiment 10：
Raw material radix fici simplicissimatis extractive 8g, angelica extract 5g, Ganodenna Lucidum P.E 1g are weighed, adds supplementary product starch 15g systems
Grain, magnesium stearate 2g, dextrin 15, microcrystalline cellulose 15g, particle is uniformly made, loads capsule, obtain capsule.
Embodiment 11：
Raw material radix fici simplicissimatis extractive 80g, angelica extract 60g, Ganodenna Lucidum P.E 30g are weighed, adds supplementary product starch
200g pelletizes, magnesium stearate 20g, dextrin 100g, microcrystalline cellulose 100g, and particle is uniformly made, tabletting, obtains tablet.
Embodiment 12：
Raw material radix fici simplicissimatis extractive 30g, angelica extract 20g, Ganodenna Lucidum P.E 10g are weighed, adds supplementary product starch 60g
Granulation, magnesium stearate 3g, dextrin 30g, microcrystalline cellulose 30g, particle is uniformly made, tabletting, obtains tablet.
Embodiment 13：
Raw material radix fici simplicissimatis extractive 70g, angelica extract 50g, Ganodenna Lucidum P.E 35g are weighed, adds supplementary product starch
200g pelletizes, magnesium stearate 20g, dextrin 150g, microcrystalline cellulose 150g, and particle is uniformly made, tabletting, obtains tablet.
Embodiment 14：
Raw material radix fici simplicissimae water extract 8g, Radix Angelicae Sinensis water extract 5g, ganoderma lucidum water extract 1g are weighed, adds supplementary product starch
15g pelletizes, magnesium stearate 2g, dextrin 15, microcrystalline cellulose 15g, and particle is uniformly made, and loads capsule, obtains capsule.
Embodiment 15：
Raw material radix fici simplicissimae water extract 80g, Radix Angelicae Sinensis water extract 60g, ganoderma lucidum water extract 30g are weighed, adds auxiliary material
Starch 200g pelletizes, magnesium stearate 20g, dextrin 100g, microcrystalline cellulose 100g, and particle is uniformly made, tabletting, obtains tablet.
Embodiment 16：
Raw material radix fici simplicissimae ethanol extract 30g is weighed, Radix Angelicae Sinensis ethanol extract 20g, ganoderma lucidum ethanol extract 10g, is added
Enter supplementary product starch 60g granulations, magnesium stearate 3g, dextrin 30g, microcrystalline cellulose 30g, particle is uniformly made, tabletting, obtains piece
Agent.
Embodiment 17：
Raw material radix fici simplicissimae ethanol extract 8g, Radix Angelicae Sinensis ethanol extract 5g, ganoderma lucidum ethanol extract 1g are weighed, routinely
Method adds pharmaceutic adjuvant and particle is uniformly made, and tabletting, obtains tablet.
Embodiment 18：
Raw material radix fici simplicissimae ethanol extract 80g is weighed, Radix Angelicae Sinensis ethanol extract 60g, ganoderma lucidum ethanol extract 30g, is pressed
Conventional method adds pharmaceutic adjuvant and particle is uniformly made, and tabletting, obtains tablet.
Embodiment 19：
Weigh raw material radix fici simplicissimae n-butanol extract 10g, Radix Angelicae Sinensis n-butanol extract 8g, ganoderma lucidum n-butanol extract
3g, pharmaceutic adjuvant is added according to a conventional method particle is uniformly made, loaded capsule, obtain capsule.
Embodiment 20：
Weigh raw material radix fici simplicissimae n-butanol extract 60g, Radix Angelicae Sinensis n-butanol extract 50g, ganoderma lucidum n-butanol extract
25g, pharmaceutic adjuvant is added according to a conventional method particle is uniformly made, loaded capsule, obtain capsule.
Embodiment 21：
Weigh raw material radix fici simplicissimae ligroin extraction 15g, Radix Angelicae Sinensis ligroin extraction 10g, ganoderma lucidum ligroin extraction
5g, pharmaceutic adjuvant is added according to a conventional method particle is uniformly made, tabletting, obtain tablet.
Embodiment 22：
Weigh raw material radix fici simplicissimae ligroin extraction 40g, Radix Angelicae Sinensis ligroin extraction 40g, ganoderma lucidum ligroin extraction
20g, particle is uniformly made according to a conventional method, tabletting, obtains tablet.
Embodiment 23：
Weigh raw material radix fici simplicissimae ligroin extraction 20g, Radix Angelicae Sinensis ligroin extraction 15g, ganoderma lucidum ligroin extraction
8g, particle is uniformly made according to a conventional method, tabletting, obtains tablet.
Embodiment 24：
Weigh raw material radix fici simplicissimae ethyl acetate extract 35g, Radix Angelicae Sinensis ethyl acetate extract 30g, ganoderma lucidum ethyl acetate
Extract 15g, particle is uniformly made according to a conventional method, tabletting, obtains tablet.
Embodiment 25：
Weigh raw material radix fici simplicissimae ethyl acetate extract 30g, Radix Angelicae Sinensis ethyl acetate extract 20g, ganoderma lucidum ethyl acetate
Extract 10g, particle is uniformly made according to a conventional method, tabletting, obtains tablet.
Above-mentioned tablet, capsule can be prepared into specification as 5mg/ pieces, 10mg/ pieces, 20mg/ according to customary preparation methods
Piece, 0.5g/ pieces, or specification is prepared into as different sizes such as 5mg/ grains, 10mg/ grains, 20mg/ grains, 0.5g/ grains.
Beneficial effects of the present invention are proved below by specific pharmacy test：
First, the influence of model mice immunologic function endoxan is injected intraperitoneally
1. research purpose：Ling Gui Johnson ＆ Johnson particle is by radix fici simplicissimae, Radix Angelicae Sinensis and ganoderma lucidum, and dose ratio is radix fici simplicissimae：When
Return：Ganoderma lucidum=3:2:1 (similarly hereinafter), investigate the influence that Ling Gui Johnson ＆ Johnson's particles cause immunosuppressed mice immunologic function to endoxan.
2. experiment material
2.1 experimental animal
160 SPF level KM mouse, full ♂, 20 ± 2g of body weight are real by People's Hospital, Sichuan Prov. of Sichuan Academy of Medical Sciences
Institute of Botany offer, animal credit number are provided：SCXK (river) 2013-15.
2.2 medicines and reagent
Ling Gui Johnson ＆ Johnson particle is made up of radix fici simplicissimae, Radix Angelicae Sinensis and ganoderma lucidum, and drug dose ratio is radix fici simplicissimae：Radix Angelicae Sinensis：Spirit
Sesame=3:2:1, from pharmaceutical college of Chengdu University of Traditional Chinese Medicine preparation research room；Parenteral solution endoxan, the permanent auspicious medical stock in Jiangsu
Part Co., Ltd, numbering：111819；India ink, Shanghai Ming Bo bio tech ltd.
2.3 instrument and equipment
FA1204L electronic balances, Shanghai Yue Ping scientific instrument Co., Ltd；WH-3 vortex oscillation instrument, the analysis of Shanghai Luxi
Instrument Co., Ltd., Factory；TDZ5-WS centrifuges, Hunan Xiang Yi Laboratory Instruments development corporation, Ltd.；HH.W21-420S thermostatted waters
Bath cabinet, Shanghai leap Medical Devices Co., Ltd.；The limited public affairs of optical instrument of holding high up are composed in PQF-60 type research fluorescence microscopes, Shanghai
Department.
3. experimental method
3.1 packet administrations
After 220 mouse adaptability nursing 3d 11 groups, i.e. blank group, model group, radix fici simplicissimae will be randomly divided into by body weight
Group (3.2g/kg), ganoderma lucidum group (3.2g/kg), when be grouped into (3.2g/kg), radix fici simplicissimae+ganoderma lucidum group (3.2g/kg), radix fici simplicissimae
+ when be grouped into (3.2g/kg), ganoderma lucidum+when be grouped into (3.2g/kg), Ling Gui Johnson ＆ Johnson particle high (6.4g/kg), in (3.2g/kg), low
(1.6g/kg) three dosage groups, every group 20.Daily gavage gives relative medicine 1 time, and blank group and model group are given in equal volume
Distilled water, administered volume 10ml/kg, successive administration 10d.In addition to blank group, remaining each group is in administration 2d intraperitoneal injections
The endoxan that 75mg/kg is newly prepared, continuous 3d prepare immunosuppressed mice model.
3.2 Carbon grain Kuo clear law determines non-specific immune function
After 11d last doses 30min, 10 mouse tail vein injection india ink 0.01ml/g (injections are randomly selected
It is preceding to use 10 times of normal saline dilution), 15min eye sockets take blood 40ul to add in 4ml 0.1%NaCO3 solution, after fully mixing
Absorbance is determined at 600nm, using 0.1%NaCO3 solution as blank well, calculates phagocyte imdex and phagocytic index.
3.3 Thymus and Spleen indexes detect
By 1h after the remaining 10 mouse administration of each group, take off cervical vertebra and put to death, then clip thymus gland and spleen, and weigh immediately,
Calculate its Thymus and Spleen index.
4. experimental result：
Influence of the 4.1 Ling Gui Johnson ＆ Johnson particles to immunosuppressed mice organ index
Influence of the Ling Gui Johnson ＆ Johnson particle of table 1 to immunosuppressed mice organ index
Note：Compared with blank group,#P<0.05,##P<0.01；Compared with model group,*P<0.05,**P<0.01。
As shown in Table 1, compared with blank group, model group mouse phagocyte imdex, phagocytic index, thymus index and spleen
Index is all decreased obviously (P<0.05) the i.e. model success of model mice immunologic hypofunction, is illustrated；Compared with model group, respectively two-by-two
Compatibility group and each dosage group of Ling Gui Johnson ＆ Johnson particle can significantly improve These parameters (P<0.05), wherein high, middle dose group carbon granules
Clean up index, phagocytic index and index and spleen index and have notable significant difference (P<0.01), ganoderma lucidum group and when be grouped into mouse thymus
Also has significant difference (P with index and spleen index<0.05)；In addition each dosage of Ling Gui Johnson ＆ Johnson particle is to immunosuppressed mice These parameters
Influence be better than compatibility group two-by-two, and the latter is better than three taste prescriptions use, has after prompting Ling Gui Johnson ＆ Johnson particle each component compatibility
There is synergistic function.Data above shows there is Synergistic between the herbal medicine of Ling Gui Johnson ＆ Johnson particle three, leads to simultaneously
After crossing dose compatibility of the present invention, total dosage of Ling Gui Johnson ＆ Johnson particle is administered by 1.6g/kg, and its curative effect is substantially better than the five fingers hair
Peach, ganoderma lucidum and Radix Angelicae Sinensis be used alone or combination of two application after (by 3.2g/kg dosage be administered) the effect of, and with count
Learn meaning.
2nd, to the influence of immunosuppressed mice immunologic function
1. research purpose：Investigate Ling Gui Johnson ＆ Johnson's particles (radix fici simplicissimae, ganoderma lucidum, Radix Angelicae Sinensis) and immunosupress is caused to hydrocortisone
The influence of T lymphocyte subsets in spleen of mice immunized.
2. experiment material
2.1 experimental animal
110 SPF level KM mouse, full ♂, 20 ± 2g of body weight are real by People's Hospital, Sichuan Prov. of Sichuan Academy of Medical Sciences
Institute of Botany offer, animal credit number are provided：SCXK (river) 2013-15.
2.2 medicines and reagent
Ling Gui Johnson ＆ Johnson particle (radix fici simplicissimae, ganoderma lucidum, Radix Angelicae Sinensis) is made by oneself according to a conventional method；Hydrocortisone parenteral solution, Tianjin
Jin Yao pharmaceutcal corporation, Ltds；CD3, CD4, CD8 monoclonal antibody, FITC- rabbit-anti rat monoclonal antibodies, are purchased from Wuhan Biological Products Inst.；
Lymphocytes separating solution, the production of the factory of Shanghai reagent two.
2.3 instrument and equipment
FA1204L electronic balances, Shanghai Yue Ping scientific instrument Co., Ltd；WH-3 vortex oscillation instrument, the analysis of Shanghai Luxi
Instrument Co., Ltd., Factory；TDZ5-WS centrifuges, Hunan Xiang Yi Laboratory Instruments development corporation, Ltd.；HH.W21-420S thermostatted waters
Bath cabinet, Shanghai leap Medical Devices Co., Ltd.；The limited public affairs of optical instrument of holding high up are composed in PQF-60 type research fluorescence microscopes, Shanghai
Department.
3. experimental method
3.1 packet administrations
After 160 mouse adaptability nursing 3d 8 groups, i.e. blank group, model group, radix fici simplicissimae will be randomly divided into by body weight
Group, ganoderma lucidum group, work as grouping, radix fici simplicissimae+ganoderma lucidum group, radix fici simplicissimae+when be grouped into, ganoderma lucidum+when be grouped into, Ling Gui Johnson ＆ Johnson particle is high,
In, low three dosage groups, every group 10.Daily gavage gives relative medicine 1 time, and blank group and model group give isometric distillation
Water, administered volume 10ml/kg, successive administration 10d.In addition to blank group, remaining each group is in administration 2d intraperitoneal injections 75mg/kg
The endoxan newly prepared, continuous 3d prepare immunosuppressed mice model [1].
3.2T lymphocyte subgroups percentage detects
Whole blood lymphocyte is separated with lymphocytes separating solution, it is 1 × 107/ml then to adjust cell concentration.Take
100ul is added in test tube, adds 100ul rat anti-mouse CD3 or CD4 or CD8 monoclonal antibodies, 4 DEG C of incubation 30min, then use
Hanks liquid is washed 3 times, and often pipe adds the rabbit-anti rat monoclonal antibody of 100ul fluorescein isothiocyanates (FITC) mark, then 4 DEG C are incubated
30min, Hanks liquid drip piece after washing 3 times, and 200 lymphocytes are observed under fluorescence microscope, calculate fluorecyte percentage.
4. experimental result
Influence of the 4.1 Ling Gui Johnson ＆ Johnson particles to immunosuppressed mice t lymphocyte subset group
Influence of the Ling Gui Johnson ＆ Johnson particle of table 2 to immunosuppressed mice t lymphocyte subset group
Note：Compared with blank group,#P<0.05,##P<0.01；Compared with model group,*P<0.05,**P<0.01。
As shown in Table 2, compared with blank group, model group mouse CD3, CD4, CD8 percentage substantially reduces, CD4/CD8 ratios
Value is obviously reduced.Compared with model group, ganoderma lucidum group, when be grouped into, two-by-two compatibility group and each dosage group CD3 of Ling Gui Johnson ＆ Johnson particle,
CD4, CD8 percentage substantially rise, and wherein the high middle dose group of Ling Gui Johnson ＆ Johnson particle has a great influence to CD3 and CD4 percentage, and five
Refer to wild peach group CD4 percentage and also have significant difference；In addition each dosage of Ling Gui Johnson ＆ Johnson particle is to immunosuppressed mice These parameters
Influence be better than compatibility group two-by-two, and the latter is better than three taste prescriptions use, prompts Ling Gui Johnson ＆ Johnson that particle each component has collaboration
Synergistic effect.Result above shows that Ling Gui Johnson ＆ Johnson particle can improve t lymphocyte subset group number in immunosuppressed mice body.
3rd, the influence horizontal to hyperlipidemia model lipid of mice caused by high lipoprotein emulsion
1. experimental animal and packet
With experiment one.
2. experimental method
11d, administered volume 0.2mL/10g is administered in each group animal continuous gavage.Give and distill except the daily gavage of blank group
Water 2 times is outer, and remaining each group morning gavage gives high lipoprotein emulsion 0.5mL/ only, afternoon gastric infusion, continuous 10d.Dosage is same
Experiment one, before last dose mouse fasting can't help water 12h, 1h mouse pluck eyeball and take blood (testing 11d) after last dose,
3000r/min centrifuges 5min, separates serum, illustrates to carry out serum TC, TG measure according to kit.It the results are shown in Table 3.
The influence horizontal to hyperlipidemia model lipid of mice caused by high lipoprotein emulsion of table 3
Note：Compared with model group, * * P<0.01；*P<0.05；Sample measurements=sample measured value/control group measured value
Average value × 100%, TC, TG be as the relative value obtained by each measured value/control cell mean, the way is to eliminate not
With animal between batch and the otherness of reagent, make result more accurate.
The result of table 3 shows that the high lipoprotein emulsion 10d of gavage can cause model mice TG, TC notable rise, illustrate modeling into
Work(.TC, TG that radix fici simplicissimae group, ganoderma lucidum and Radix Angelicae Sinensis can not be reduced substantially when being used alone in model mice serum are horizontal, the five fingers
After wild peach group, ganoderma lucidum and Radix Angelicae Sinensis combination of two compatibility, there is reduction trend to TC, TG in mice serum, but anticipate without statistics
Justice.After radix fici simplicissimae group, ganoderma lucidum and Radix Angelicae Sinensis composition compatibility, then TC, the TG that can significantly reduce in mice serum are horizontal,
Test result indicates that pharmaceutical composition of the present invention has the function that reducing blood lipid.
Claims (10)
- A kind of 1. pharmaceutical composition for being used to improve immune function of human body, it is characterised in that：It is by following components and weight ratio Raw material composition：The parts by weight of radix fici simplicissimae 8~80, the parts by weight of Radix Angelicae Sinensis 5~60, the parts by weight of ganoderma lucidum 1~30.
- A kind of 2. pharmaceutical composition for being used to improve immune function of human body according to claim 1, it is characterised in that：The five fingers The parts by weight of wild peach 10~60, the parts by weight of Radix Angelicae Sinensis 8~50, the parts by weight of ganoderma lucidum 3~25.
- A kind of 3. pharmaceutical composition for being used to improve immune function of human body according to claim 1, it is characterised in that：The five fingers The parts by weight of wild peach 15~40, the parts by weight of Radix Angelicae Sinensis 10~40, the parts by weight of ganoderma lucidum 5~20.
- A kind of 4. pharmaceutical composition for being used to improve immune function of human body according to claim 1, it is characterised in that：The five fingers The parts by weight of wild peach 20~35, the parts by weight of Radix Angelicae Sinensis 15~30, the parts by weight of ganoderma lucidum 8~15.
- A kind of 5. pharmaceutical composition for being used to improve immune function of human body according to claim 1, it is characterised in that：The five fingers The parts by weight of wild peach 30, the parts by weight of Radix Angelicae Sinensis 20, the parts by weight of ganoderma lucidum 10.
- A kind of 6. pharmaceutical composition for being used to improve immune function of human body, it is characterised in that：It is by following components and weight ratio Raw material composition：The parts by weight of radix fici simplicissimatis extractive 8~80, the parts by weight of angelica extract 5~60, the weight of Ganodenna Lucidum P.E 1~30 Measure part.
- A kind of 7. pharmaceutical composition for being used to improve immune function of human body according to claim 1, it is characterised in that：The five fingers The parts by weight of wild peach extract 30, the parts by weight of angelica extract 20, the parts by weight of Ganodenna Lucidum P.E 10.
- A kind of 8. system for being used to improve the pharmaceutical composition of immune function of human body as described in any one in claim 1~7 Preparation Method, it is characterised in that：It comprises the following steps：S1：Weigh raw material：Radix fici simplicissimae, Radix Angelicae Sinensis and ganoderma lucidum are weighed by said components and weight ratio；S2：After raw material is well mixed, adds pharmaceutically acceptable auxiliary material and be prepared into pharmaceutically conventional pharmaceutical preparation.
- 9. a kind of preparation method for being used to improve the pharmaceutical composition of immune function of human body according to claim 8, it is special Sign is：Described pharmaceutical preparation is tablet, capsule, granule, powder, oral liquid, freeze-dried powder or parenteral solution.
- 10. the pharmaceutical composition as described in any one claim in claim 1~7 is being prepared for improving human immunity Application in function medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710724860.3A CN107334818A (en) | 2017-08-22 | 2017-08-22 | A kind of pharmaceutical composition and preparation method and purposes for being used to improve immune function of human body |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710724860.3A CN107334818A (en) | 2017-08-22 | 2017-08-22 | A kind of pharmaceutical composition and preparation method and purposes for being used to improve immune function of human body |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107334818A true CN107334818A (en) | 2017-11-10 |
Family
ID=60215063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710724860.3A Pending CN107334818A (en) | 2017-08-22 | 2017-08-22 | A kind of pharmaceutical composition and preparation method and purposes for being used to improve immune function of human body |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107334818A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108308496A (en) * | 2018-02-05 | 2018-07-24 | 河源市金源绿色生命有限公司 | A kind of herbaceous plant beverage and preparation method thereof for being conducive to improve immunity |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108606996A (en) * | 2016-12-12 | 2018-10-02 | 冯正美 | It is a kind of that there is the pharmaceutical composition for improving immune function |
-
2017
- 2017-08-22 CN CN201710724860.3A patent/CN107334818A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108606996A (en) * | 2016-12-12 | 2018-10-02 | 冯正美 | It is a kind of that there is the pharmaceutical composition for improving immune function |
Non-Patent Citations (3)
| Title |
|---|
| 柴瑞震: "《《黄帝内经》和《本草纲目》中的中药养生全典》", 31 January 2014, 黑龙江科学技术出版社 * |
| 网友回答（2）: "灵芝和当归煮着喝好吗", 《HTTPS://MUZHI.BAIDU.COM/MIPQUESTION/1302773316741089899.HTML》 * |
| 耿卫朴等: "灵芝多糖和当归多糖促进人外周血T淋巴细胞增殖和分泌IFN-γ", 《中国药理学通报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108308496A (en) * | 2018-02-05 | 2018-07-24 | 河源市金源绿色生命有限公司 | A kind of herbaceous plant beverage and preparation method thereof for being conducive to improve immunity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102145128B (en) | Medicinal composition for preventing and treating cardiac and cerebral vascular diseases and preparation method thereof | |
| CN111110824A (en) | Medicinal composition for strengthening body resistance and rescuing lung and application thereof | |
| CN106924406A (en) | A kind of pharmaceutical composition of adjuvant drug for treating AIDS and preparation method thereof | |
| CN103169737A (en) | Composite of Antrodia camphorata entity and shell-broken ganoderma lucidum spore powder and application thereof in immune adjustment | |
| CN102356872B (en) | A combination food for reducing blood fat | |
| CN102512485A (en) | Traditional Chinese medicine for treating acute hepatitis, chronic hepatitis and hepatic fibrosis | |
| CN107334818A (en) | A kind of pharmaceutical composition and preparation method and purposes for being used to improve immune function of human body | |
| CN1056755C (en) | Medicine of curing hepatitis | |
| CN104644656A (en) | Application of 20(R)-ginsenoside Rg3 in preparation of medicament for relieving or/and treating asthma and medicament | |
| CN106038702B (en) | Anti-fatigue composition, preparation method and application thereof | |
| CN103599265B (en) | A kind of compound traditional Chinese medicine for radiation protection | |
| CN104688723A (en) | Application of anhydroicaritin in preparation of medicine for treating anaemia | |
| CN101757016A (en) | Medicine composition for treating flu and preparation method thereof | |
| CN102552440B (en) | Anti-asthmatic and anti-inflammatory medicament and preparation method and application thereof | |
| CN106377600A (en) | Traditional Chinese medicine composition and application thereof | |
| CN101695536B (en) | Chinese medicinal composition for preventing and treating influenza A virus subtype H1N1 | |
| CN102225155B (en) | Medicament composition for treating pulmonary fibrosis | |
| CN106344549A (en) | Application of rhein in preparation of drugs for preventing and/or treating hand-foot-and-mouth disease | |
| CN101874858B (en) | Traditional Chinese medicine for treating virus hepatitis and preparation method thereof | |
| CN102846965A (en) | Traditional Chinese medicine preparation capable of resisting HIV and improving immunity and preparation method of traditional Chinese medicine | |
| CN104352531A (en) | Application of ophiocordyceps longissima (kobayasi) sung in preparation of liver protection medicine and health care products | |
| CN102406172A (en) | Health food for enhancing immunity and preparation method thereof | |
| CN104644661A (en) | Application of 20(R)-ginsenoside Rg3 in preparation of medicament for relieving or/and treating hepatitis B and medicament | |
| CN103585212B (en) | The application of Dorema ammoniacum resin extract in preparation treatment AIDS-treating medicine | |
| CN104042678B (en) | A kind of treat hyperlipemia pharmaceutical composition and preparation method and purposes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171110 |